Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). (2021)


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 32926420

Publication URI:

Type: Journal Article/Review

Volume: 193

Parent Publication: British journal of haematology

Issue: 1

ISSN: 0007-1048